4/3/2014 12:08:25 PM
HAMPTON, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1 (T cell immunoglobulin and mucin domain), which is upregulated in several cancers, including renal and ovarian carcinomas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by